InsiderSignalSign in

← Insider buys

ABEO

Abeona Therapeutics Inc. · Healthcare

Insiders sold $3.3M of Abeona Therapeutics Inc. in the last 12 months and bought none

$0Bought, 12 mo

$3.3MSold, 12 mo

$263.0MMarket cap

ABEO over the last year

No insider buys filed in this year

ABEO after insider buys

3 months after each buy, from the first price a copier could get.

+23.8%Average

+16.7 ptsVs S&P 500

4 of 5Higher

5 buys since 2016 with 3 months of prices.

Every filing

64 insider filings since 2016, newest first

Vishwas Seshadri · Chief Executive Officer

$101K−1.5%Sep 29

Joseph Walter Vazzano · Chief Financial Officer

$47K−1.9%Sep 29

Brendan M. O'Malley · SVP and Chief Legal Officer

$35K−1.6%Sep 29

Madhav Vasanthavada · Chief Commercial Officer

$25K−1.7%Sep 29

Mark Alvino · Director

$88K−19.5%Sep 1

Joseph Walter Vazzano · Chief Financial Officer

$173K−4.8%Jul 9

Vishwas Seshadri · Chief Executive Officer

$473K−4.9%Jul 9

Brendan M. O'Malley · SVP and Chief Legal Officer

$84K−2.7%Jul 9

Madhav Vasanthavada · Chief Commercial Officer

$88K−4.2%Jul 9

Leila Alland · Director

$65K−6.3%Jul 2

Christine Berni Silverstein · Director

$104K−13.2%Jun 15

Brendan M. O'Malley · SVP and Chief Legal Officer

$60K−2.5%Jun 10

Joseph Walter Vazzano · Chief Financial Officer

$265K−8.7%Jun 10

Madhav Vasanthavada · Chief Commercial Officer

$52K−3.1%Jun 10

Vishwas Seshadri · Chief Executive Officer

$302K−3.9%Jun 10

Mark Alvino · Director

$35K−8.0%May 22

Eric Crombez · Director

$145K−41.0%May 15

Madhav Vasanthavada · Chief Commercial Officer

$33K−1.7%May 11

Vishwas Seshadri · CEO

$131K−2.0%Mar 31

Eric Crombez · Director

$83K−20.0%Feb 2

Donald A. Wuchterl · Director

$75K−8.0%Feb 2

Leila Alland · Director

$92K−9.0%Feb 2

Joseph Walter Vazzano · CFO

$100K−3.0%Jan 22

Vishwas Seshadri · CEO

$372K−5.0%Jan 22

Brendan M. O'Malley · SVP and General Counsel

$72K−3.0%Jan 22

Mark Alvino · Director

$71K−22.0%Jan 21

Vishwas Seshadri · CEO

$133K−2.0%Dec 29

Mark Alvino · Director

$117K−41.0%Jun 20

Christine Berni Silverstein · Director

$116K−29.0%Jun 20

Leila Alland · Director

$52K+15.0%May 20

Vishwas Seshadri · CEO

$32K+2.0%Apr 29

Brendan M. O'Malley · SVP and General Counsel

$28K+5.0%Apr 26

Vishwas Seshadri · CEO

Mark Alvino · Director

$36K−10.0%Jan 22

Faith L. Charles · Director

$41K−11.0%Sep 29

Leila Alland · Director

$28K−9.0%Sep 29

Vishwas Seshadri · CEO

$81K+4.0%Sep 29

Brendan M. O'Malley · SVP and General Counsel

$26K−9.0%Oct 8

Edward Carr · CFO

$31K−7.0%Oct 8

Michael Amoroso · CEO

$49K−7.0%Oct 4

Sco Capital Partners LLC · Director and 10% owner

$161K−1.0%May 5

Edward Carr · Chief Accounting Officer

$101K−22.0%Apr 5

Michael Amoroso · CEO

$85K−7.0%Apr 2

Sco Capital Partners LLC · Director and 10% owner

$179K−1.0%Mar 19

Paul Elliot Mann · Director

$109K−100.0%Feb 23

Todd Wider · Director

$601K−91.0%Feb 23

Paul Elliot Mann · Director

$310K−100.0%Feb 19

Todd Wider · Director

$753K−54.0%Feb 19

Sco Capital Partners LLC · Director and 10% owner

$357K−1.0%Feb 18

Sco Capital Partners LLC · Director and 10% owner

$723K−2.0%Feb 10

About Abeona Therapeutics Inc.

Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio.

Filings come from SEC EDGAR and prices from daily closes. Not investment advice.